Cancer Patients With a Healthier Thymus Live Longer — Here's Why

There's a small gland behind your breastbone that most doctors stopped worrying about once you hit puberty. It trains immune cells when you're young, then gradually fills with fat, and medicine more or less retired it from active duty. Two papers dropped on March 18 in Nature from the same team at Harvard's Mass General Brigham, and they make a compelling, slightly embarrassing case that retiring it was a mistake — for longevity, for cancer risk, and for whether immunotherapy works at all.

The Organ That Medicine Retired Too Early

The thymus is a training ground for T cells — the immune soldiers that hunt down infections and rogue cancer cells. After puberty it shrinks, and the long-standing assumption was that the body compensates by recycling existing T cells just fine. Job done, organ irrelevant. Hugo Aerts, director of the AI in Medicine Program at Mass General Brigham, wasn't buying it. His suspicion grew sharper after a landmark 2023 New England Journal of Medicine paper showed adults who'd had their thymus surgically removed were dying earlier and getting sicker across a wide range of diseases — sometimes decades after the procedure. Which raised an obvious follow-up: if a gone thymus does that, what does a quietly deteriorating one do?

Why Every Previous Study Missed This

Here's the frustrating part: earlier research kept concluding the thymus was fully gone in 60–75% of adults. Not because it was, necessarily, but because radiologists were eyeballing CT scans and guessing at fatty versus functional tissue. Blunt instrument, blunt results. No detectable signal, no link to outcomes.

Aerts' team trained a deep learning model on 5,674 CT scans to read subtle structural patterns in the thymic region that human eyes miss entirely. The output is a score from 0 to 100 — continuous, not a rough binary guess. They locked the model, then ran it on two separate cohorts it had never touched: 25,031 people from the National Lung Screening Trial and 2,581 from the Framingham Heart Study. Different populations, different scanners, different everything.

How Does Thymic Health Predict Death, Cancer, and Heart Disease?

In the NLST — heavy smokers, 55 to 74 — the top thymic health quarter had a 12-year mortality rate of 13.4%. The bottom quarter: 25.5%. That gap held after adjusting for smoking, age, diabetes, hypertension, COPD, heart disease, and eleven other known risk factors. The signal didn't budge. Framingham, despite being a much healthier and younger cohort, pointed the same direction.

Lung cancer incidence was 36% lower in the high thymic health group. Cardiovascular mortality dropped 63% in the NLST and up to 92% in Framingham's top group — though the authors flag the small absolute numbers there. Pulmonary, metabolic, and digestive disease deaths all tracked down with better thymic health too. Every category they looked at moved the same way.

The Immunotherapy Connection Nobody Saw Coming

The second paper is where things get clinically urgent. Aerts' team looked at more than 1,200 cancer patients receiving immune checkpoint inhibitors — the class of drugs that essentially take the brakes off the immune system to let it attack tumours. Immunotherapy has transformed cancer treatment for some patients and done almost nothing for others, and nobody has had a great explanation for why.

Thymic health scores predicted it. Patients with better thymic health had a 37% lower risk of their cancer progressing and a 44% lower risk of death — after adjusting for tumour type, treatment regimen, and other patient factors. The team also found that thymic health correlated with T cell receptor diversity, a measure of how varied and capable the immune repertoire actually is. That's the biological mechanism that makes the result make sense: immunotherapy works by activating T cells, and a thymus that's been maintaining a richer T cell pool gives you more to work with.

What the Field Still Doesn't Know

Causality remains unsolved. This is observational work — it shows association, not proof that thymic decline causes bad outcomes rather than reflecting them. That distinction matters enormously for whether the thymus becomes a clinical target or just a passive marker. Prospective, interventional trials are the only way to answer it, and they haven't been done.

Both populations skew white and older, so the findings need validating in diverse groups. The model uses population-specific cut-offs — no universal thresholds exist yet for clinical use. What does exist is the ARPA-H Thymus Rejuvenation programme, already funded, aiming to restore thymic function in adults. And now, two papers in the same issue of Nature giving it a clearer scientific mandate than it had a week ago.

• Ageing isn't the whole story — People of the same age showed dramatically different thymic health scores, which means decay rate is likely shaped by lifestyle choices, not just birthdays.
• Immunotherapy patients could be screened — If thymic health predicts treatment response, a routine CT scan taken before starting immunotherapy could help oncologists set expectations and adjust plans.
• Inflammation is a lever — Chronic CRP elevation, smoking, and obesity all tied to worse thymic scores — meaning there may be modifiable pathways to slow the decline before drugs are even needed.

"What these two studies show is that almost this forgotten organ, the thymus, may actually play a very central role in our health throughout life." — Hugo Aerts, Nature, 2026.